ArticleCardiovascular & hematological disorders drug targets2022
Oakmoss Exhibits Antihyperglycemic Activity in Streptozotocin-Induced Diabetic Rats.
Article in Cardiovascular & hematological disorders drug targets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Chemical Profiling and In Vitro Evaluation of Bioactive Properties ofPlants (Basel, Switzerland) · 2025Article
- Lichens in Pharmacological Action: What Happened in the Last Decade?The Eurasian journal of medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
aimsThe study aimed to assess the antidiabetic effect of oakmoss.
backgroundLichens species are dual organisms consisting of a mycobiont (Fungi) and a photoautotrophic partner (Algae). They are widely used in traditional medicine as a treatment for diabetes.
objectiveThis study was designed to assess the antihyperglycemic activity as well as the antihyperlipidemic capacity of oakmoss (Evernia prunastri (L.)) in normal and streptozotocin(STZ)- induced diabetic rats.
methodsThis study has evaluated the effects of aqueous extract of oakmoss at a dose of 60 mg/kg on blood glucose levels and lipid profile in normal and STZ-induced diabetic rats. Histopathological examination of the liver, determination of glycogen content in liver and skeletal muscles (EDL and soleus), antioxidant activity, and phytochemical investigation were also performed.
resultsBoth single and repeated oral doses of oakmoss (60 mg/kg) significantly reduced blood glucose, triglycerides, and very-low-density lipoprotein (VLDL) levels in diabetic rats. Furthermore, repeated oral administration of oakmoss for 7 days ameliorated the liver function by increasing its glycogen content and improving its histological architecture in treated diabetic rats. In addition, the aqueous extract of oakmoss exhibited antioxidant activity and showed richness in certain phytochemicals, especially in phenolic acids and flavonoids.
conclusionOakmoss, a lichen species, exhibits a potential effect on improving hyperglycemia and hypertriglyceridemia in diabetic rats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.